Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOS-1: Epcoritamab in Relapsed/Refractory Marginal Zone Lymphoma
2025-524879-23-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in extranodal marginal zone B-cell lymphoma (EMZL), splenic marginal zone lymphoma (SMZL), nodal marginal zone B-cell lymphoma (NMZL) and 1 more, sponsored by University Hospital Ulm. Primary endpoint: Complete response rate (CRR). Planned start Oct 2026; status: authorised.
02
Drugs
epcoritamab
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2025-524879-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524879-23-00.